Resources from the same session
Predicting Risk of Recurrence in HR-positive, HER2-negative Early Breast Cancer: A Focus on Clinicopathological Factors
Presenter: All Speakers
Session: AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice
Resources:
Webcast
Tools to Guide Risk Assessment and Adjuvant Treatment Decisions in HR-positive, HER2-negative Early Breast Cancer: A Focus on Best Practices
Presenter: All Speakers
Session: AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice
Resources:
Webcast
Impact of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Recent Evidence
Presenter: All Speakers
Session: AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice
Resources:
Webcast
Optimizing the Use of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Patient Management
Presenter: All Speakers
Session: AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice
Resources:
Webcast
Questions and Take-Home Learnings
Presenter: All Speakers
Session: AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice
Resources:
Webcast